Tradestie Institutional Equity Comparison Engine
CVM vs BCRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BCRX Overall Edge
BCRX Captures Institutional Edge (4โ0 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioCryst Pharmaceuticals Inc (BCRX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus BCRX at 8.9x Forward P/E and 48.8% operating margin (+13.1% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against BCRX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
BCRX
CVM 23.0x vs BCRX 8.9x Fwd P/E
Growth & Margin Winner
BCRX
Op Margin 0.0% vs 48.8% ยท YoY -62.7% vs +13.1%
Momentum & Technical Winner
BCRX
1Y -77.5% vs +9.1% ยท 52W Pos 10% vs 26%
Options & Structure Winner
BCRX
BREAKDOWN (N/A IV) vs BREAKDOWN (12th %ile IV)
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap
$20.9M
1M Return
-11.17%
1Y Return
-77.48%
Forward P/E
23.0x
Unified AI Score
56.6 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
BCRX
NASDAQ
BioCryst Pharmaceuticals Inc
Biological Products, (No Disgnostic Substances)
$7.53
-1.05% 1D
Market Cap
$1.9B
1M Return
-3.34%
1Y Return
+9.13%
Forward P/E
8.9x
Unified AI Score
43.3 / 100
HOLD
Tech 24.0
Fund 59.0
Flow 67.0
Mom 68.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CVM -77.48%
BCRX +9.13%
Spread: +82.34 pp (BCRX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | BCRX Revenue | CVM Op. Margin | BCRX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $20M | N/A | -456.2% | BCRX |
| FY2019 | N/A | $50M | N/A | -203.7% | BCRX |
| FY2020 | N/A | $20M | N/A | -981.1% | BCRX |
| FY2021 | N/A | $160M | N/A | -113.1% | BCRX |
| FY2022 | N/A | $270M | N/A | -54.8% | BCRX |
| FY2023 | N/A | $330M | N/A | -31.3% | BCRX |
| FY2024 | N/A | $450M | N/A | -0.6% | BCRX |
| FY2025 | N/A | $870M | N/A | 39.0% | BCRX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CVM | BCRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $20.9M | $1.9B | Larger Scale | BCRX |
| Trailing P/E Ratio Valuation | 23.0x | 13.0x | Lower Multiple | BCRX |
| Forward P/E Ratio Valuation | 23.0x | 8.9x | Lower Multiple | BCRX |
| Revenue Growth (YoY) Growth | -62.7% | +13.1% | Higher Growth | BCRX |
| Operating Margin (TTM) Profitability | 0.0% | 48.8% | Higher Margin | BCRX |
| Net Profit Margin Profitability | 0.0% | -37.4% | Higher Margin | CVM |
| Return on Equity (ROE) Capital Efficiency | -252.5% | -1925.4% | Higher ROE | CVM |
| 52-Week Range Position Momentum | 10% ($1โ$8) | 26% ($6โ$11) | Stronger Trend | BCRX |
| Beta / 30D Volatility Risk Regime | 0.65ฮฒ ยท 120% Vol | 0.77ฮฒ ยท 42% Vol | Lower Realized Risk | BCRX |
| Unified Institutional Score Composite Signal | 56.6 / 100 (HOLD) | 43.3 / 100 (HOLD) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CVM vs BCRX Buy Guide
CVM
BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BCRX
BREAKDOWN
92d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CVM nor BCRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.